424 related articles for article (PubMed ID: 17299813)
1. Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy.
Baldrick P; Richardson D; Woroniecki SR; Lees B
J Appl Toxicol; 2007; 27(4):399-409. PubMed ID: 17299813
[TBL] [Abstract][Full Text] [Related]
2. Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL) for the treatment of grass pollen allergy.
Baldrick P; Richardson D; Wheeler AW; Woroniecki SR
J Appl Toxicol; 2004; 24(4):261-8. PubMed ID: 15300713
[TBL] [Abstract][Full Text] [Related]
3. A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy.
Reeve L; Baldrick P; Hewings S; Skinner M
J Appl Toxicol; 2012 Aug; 32(8):608-16. PubMed ID: 21919021
[TBL] [Abstract][Full Text] [Related]
4. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine.
Patel P; Salapatek AM
Expert Rev Vaccines; 2006 Oct; 5(5):617-29. PubMed ID: 17181436
[TBL] [Abstract][Full Text] [Related]
5. Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL).
Hopkins M; Lees BG; Richardson DG; Woroniecki SR; Wheeler AW
Allergol Immunopathol (Madr); 2001; 29(6):245-54. PubMed ID: 11834183
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.
Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B
J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670
[TBL] [Abstract][Full Text] [Related]
7. Allergoid-specific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Th1-adjuvanted allergy vaccine.
von Baehr V; Hermes A; von Baehr R; Scherf HP; Volk HD; Fischer von Weikersthal-Drachenberg KJ; Woroniecki S
J Investig Allergol Clin Immunol; 2005; 15(4):234-41. PubMed ID: 16433203
[TBL] [Abstract][Full Text] [Related]
8. Reproduction and juvenile animal toxicology studies in the rat with a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL(®)) for the treatment of grass pollen allergy.
Baldrick P; Hewings S; Skinner M
Reprod Toxicol; 2011 Nov; 32(3):322-8. PubMed ID: 21782016
[TBL] [Abstract][Full Text] [Related]
9. Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis.
Rosewich M; Lee D; Zielen S
Hum Vaccin Immunother; 2013 Jul; 9(7):1523-31. PubMed ID: 23584250
[TBL] [Abstract][Full Text] [Related]
10. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro).
McCormack PL; Wagstaff AJ
Drugs; 2006; 66(7):931-8. PubMed ID: 16740007
[TBL] [Abstract][Full Text] [Related]
11. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study.
Pfaar O; Barth C; Jaschke C; Hörmann K; Klimek L
Int Arch Allergy Immunol; 2011; 154(4):336-44. PubMed ID: 20975285
[TBL] [Abstract][Full Text] [Related]
12. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections.
Drachenberg KJ; Wheeler AW; Stuebner P; Horak F
Allergy; 2001 Jun; 56(6):498-505. PubMed ID: 11421893
[TBL] [Abstract][Full Text] [Related]
13. Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL) adjuvant: a new allergy vaccine for dust mite allergy.
Baldrick P; Richardson D; Wheeler AW
Vaccine; 2001 Dec; 20(5-6):737-43. PubMed ID: 11738737
[TBL] [Abstract][Full Text] [Related]
14. Array-based profiling of ragweed and mugwort pollen allergens.
Gadermaier G; Wopfner N; Wallner M; Egger M; Didierlaurent A; Regl G; Aberger F; Lang R; Ferreira F; Hawranek T
Allergy; 2008 Nov; 63(11):1543-9. PubMed ID: 18925891
[TBL] [Abstract][Full Text] [Related]
15. Review of L-tyrosine confirming its safe human use as an adjuvant.
Baldrick P; Richardson D; Wheeler AW
J Appl Toxicol; 2002; 22(5):333-44. PubMed ID: 12355563
[TBL] [Abstract][Full Text] [Related]
16. Safety Evaluation of PQ Birch Allergy Immunotherapy to Support Product Development.
Baldrick P; Hutchings JW; Heath MD; Skinner MA
Regul Toxicol Pharmacol; 2019 Nov; 108():104441. PubMed ID: 31425728
[TBL] [Abstract][Full Text] [Related]
17. A case of anaphylaxis to Pollinex® Quattro MPL-4.
Borgonovo L; Piconi S; Fusi A; Iemoli E
Eur Ann Allergy Clin Immunol; 2014 Jan; 46(1):46-8. PubMed ID: 24702876
[TBL] [Abstract][Full Text] [Related]
18. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.
Wheeler AW; Marshall JS; Ulrich JT
Int Arch Allergy Immunol; 2001 Oct; 126(2):135-9. PubMed ID: 11729351
[TBL] [Abstract][Full Text] [Related]
19. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses.
Puggioni F; Durham SR; Francis JN
Allergy; 2005 May; 60(5):678-84. PubMed ID: 15813815
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of IgE-binding to Art v 1, Art v 4 and Amb a 1 in mugwort-allergic patients.
Oberhuber C; Ma Y; Wopfner N; Gadermaier G; Dedic A; Niggemann B; Maderegger B; Gruber P; Ferreira F; Scheiner O; Hoffmann-Sommergruber K
Int Arch Allergy Immunol; 2008; 145(2):94-101. PubMed ID: 17823540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
